IPHARMA obtained an approval to conduct the clinical trial of a drug for post-Covid-19 rehabilitatio

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug Treamid.


The investigational drug developer is PHARMENTERPRISES LLC.


Protocol № COVID-TRE-03 "A multicenter randomized double-blind placebo-controlled pilot studyto assess efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia".


The purpose is to assess efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia.


The study will be conducted in 12 clinical sites.

Недавние посты
Архив